Shingles Vaccines Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The shingles vaccines market encompasses products designed to prevent herpes zoster (shingles) and its most common complication, postherpetic neuralgia, primarily in adults aged 50 and older. The market is dominated by recombinant zoster vaccines, with the live-attenuated vaccine having been phased out in many developed markets. Reimbursement policies in countries such as the United States and the United Kingdom have made vaccination broadly accessible, supporting steady volume growth.

• •2025 market valuation: approximately $5.36 billion, growing at a CAGR of 12.61%.
• •Recombinant subunit vaccines account for the overwhelming majority of current sales.
• •Adults aged 50+ represent the core target population across all major regions.

Population aging is the single largest structural driver, as shingles incidence rises sharply after age 50 and the pool of at-risk adults expands in nearly every developed economy. Public payer coverage in key markets has reduced out-of-pocket costs, materially lifting uptake rates. Rising awareness of postherpetic neuralgia and other complications is also pushing higher vaccination rates in both recommended and self-pay segments.

• •Expansion of the global 50+ population is increasing the addressable patient base.
• •Inclusion in national immunization programs in the US, UK, Germany, and Australia supports volume.
• •Growing clinical evidence on long-term efficacy continues to reinforce prescriber confidence.

By product type, recombinant vaccines hold the dominant share, while the market is also segmented by vaccine type, distribution channel (hospital pharmacies, retail pharmacies, and public health clinics), and patient age group. North America is the largest regional market, supported by strong reimbursement and high awareness, followed by Europe, where universal coverage in several countries sustains demand.

• •North America accounts for the largest revenue share, led by the United States.
• •Asia-Pacific is the fastest-growing region, driven by Japan, China, and Australia.
• •Retail and hospital pharmacies are the leading distribution channels globally.

What are the recent trends and outlook?

Combination vaccines that pair shingles protection with other adult immunizations are an active area of development, and pipeline candidates aim to broaden age eligibility and improve duration of protection. Geographic expansion into emerging markets, where uptake remains low, represents the most significant untapped growth opportunity. The market outlook remains strongly positive, with double-digit annual growth expected through at least the early 2030s.

• •Pipeline activity focuses on longer-lasting and combination adult vaccines.
• •Emerging-market expansion is expected to accelerate volume growth over the forecast period.
• •Public-health agencies are increasingly recommending shingles vaccination in adults under 60.